Uno studio su HER3-DXd in soggetti con tumori solidi localmente avanzati o metastatici
HERTHENA-PanTumor01 (U31402-277): studio di fase 2, multicentrico, multicoorte, in aperto, Proof of Concept di Patritumab Deruxtecan (HER3-DXd; U3-1402) in soggetti con tumori solidi localmente avanzati o metastatici
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This study is designed to assess the safety and efficacy of HER3-DXd monotherapy in subjects with refractory locally advanced unresectable or metastatic solid tumors who have been previously treated with ≥1 prior line of systemic anticancer therapy.
The primary objective of the study is to assess the efficacy of HER3-DXd monotherapy for each type of indicated locally advanced unresectable or metastatic tumor. Secondary objectives include the assessment of safety and tolerability, efficacy, and pharmacokinetics of HER3-DXd monotherapy for each type of indicated locally advanced unresectable or metastatic tumor. HER3 protein expression in tumor tissue and its relationship with HER3-DXd efficacy will also be evaluated.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Daiichi Sankyo Contact for Clinical Trial Information
- Numero di telefono: 9089926400
- Email: CTRinfo@dsi.com
Luoghi di studio
-
-
-
Camperdown, Australia, 2050
- Reclutamento
- Chris O'Brien Lifehouse
-
Chermside, Australia, 4032
- Reclutamento
- Icon Cancer Centre Chermside
-
Clayton, Australia, 3168
- Reclutamento
- Monash Medical Centre Clayton
-
Hobart, Australia, 7000
- Reclutamento
- Icon Cancer Centre Hobart
-
Hyde Park, Australia, 4812
- Reclutamento
- Icon Cancer Centre Townsville
-
-
-
-
-
Brussels, Belgio
- Reclutamento
- Cliniques Universitaires Saint-Luc
-
Edegem, Belgio, 2650
- Reclutamento
- UZA
-
Ghent, Belgio, 9000
- Reclutamento
- Universitair Ziekenhuis Gent
-
Jette, Belgio
- Reclutamento
- Universitair Ziekenhuis Brussel
-
Leuven, Belgio, 3000
- Reclutamento
- UZ Leuven
-
-
-
-
-
Toronto, Canada, M4N 3M5
- Reclutamento
- Sunnybrook Research Institute
-
Toronto, Canada, M5G2M9
- Completato
- Princess Margaret Cancer Centre
-
Vancouver, Canada, V5Z4E6
- Reclutamento
- BC Cancer - Vancouver
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Reclutamento
- Cross Cancer Institute
-
-
-
-
-
Chengdu, Cina, 610098
- Reclutamento
- West China Hospital, Sichuan University
-
Guangzhou, Cina, 510060
- Reclutamento
- Sun Yat-sen University Cancer Center
-
-
-
-
-
Daegu, Corea del Sud, 41404
- Reclutamento
- Kyungpook National University Chilgok Hospital
-
Gyeonggi-do, Corea del Sud, 410-769
- Reclutamento
- National Cancer Center
-
Seongnam, Corea del Sud, 13620
- Reclutamento
- Seoul National University Bundang Hospital
-
Seongnam, Corea del Sud, 13496
- Reclutamento
- Cha Bundang Medical Center, Cha University
-
Seoul, Corea del Sud, 05505
- Reclutamento
- Asan Medical Center
-
Seoul, Corea del Sud, 03080
- Reclutamento
- Seoul National University Hospital
-
Seoul, Corea del Sud, 03722
- Reclutamento
- Severance Hospital, Yonsei University Health System
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center
-
-
-
-
-
Bordeaux, Francia, 33000
- Reclutamento
- Chu Bordeaux
-
Dijon, Francia, 21079
- Reclutamento
- Centre Georges Franăois Leclerc
-
Lille, Francia, 59000
- Reclutamento
- Hopital Claude Huriez - Chu Lille
-
Lyon, Francia, 69008
- Reclutamento
- Centre Léon Bérard
-
Marseille, Francia, 13005
- Reclutamento
- Hăpital de La Timone
-
Nantes, Francia, 44093
- Reclutamento
- Chu Nantes - Hătel Dieu
-
Toulouse, Francia, 31100
- Reclutamento
- Institut Claudius Regaud
-
Vandœuvre-lès-Nancy, Francia, 54500
- Reclutamento
- ICL - Alexis Vautrin
-
Villejuif, Francia, 94805
- Reclutamento
- Institut Gustave Roussy
-
-
-
-
-
Frankfurt, Germania, 60488
- Reclutamento
- Krankenhaus Nordwest GmbH
-
-
-
-
-
Hidaka, Giappone, 350-1298
- Reclutamento
- Saitama Medical University International Medical Center
-
Kagoshima, Giappone, 892-0833
- Reclutamento
- HAKUAIKAI Social Medical Corporation Sagara Hospital
-
Kanagawa, Giappone, 241-8515
- Reclutamento
- Kanagawa Cancer Center
-
Kashiwa-shi, Giappone, 277-8577
- Reclutamento
- National Cancer Center Hospital East
-
Contatto:
- See Central Contact
-
Matsuyama, Giappone, 791-0245
- Reclutamento
- NHO Shikoku Cancer Center
-
Contatto:
- See Central Contact
-
Nagaizumi-cho, Giappone, 411-8777
- Reclutamento
- Shizuoka Cancer Center
-
Contatto:
- See Central Contact
-
Nagoya, Giappone, 464-8681
- Reclutamento
- Aichi Cancer Center Hospital
-
Osakasayama-shi, Giappone, 589-8511
- Reclutamento
- Kindai University Hospital
-
Contatto:
- See Central Contact
-
Saitama, Giappone, 362-0806
- Reclutamento
- Saitama Cancer Center
-
Tokyo, Giappone, 104-0045
- Reclutamento
- National Cancer Center Hospital
-
Tokyo, Giappone, 135-8550
- Reclutamento
- Cancer Institute Hospital of JFCR
-
Tokyo, Giappone, 142-8666
- Reclutamento
- SHOWA Medical University Hospital
-
Yokohama, Giappone, 232-0024
- Reclutamento
- Yokohama City University Medical Center
-
-
-
-
-
Bergamo, Italia, 24125
- Reclutamento
- Humanitas Gavazzeni
-
Genova, Italia, 16132
- Reclutamento
- IRCCS Ospedale Policlinico San Martino
-
Naples, Italia, 80131
- Reclutamento
- AOU Federico II - Oncologia Clinica
-
Verona, Italia, 37134
- Reclutamento
- Centro Ricerche Cliniche di Verona s.r.l.
-
-
-
-
-
Lørenskog, Norvegia, 1478
- Completato
- Haukeland universitetssjukehus
-
Lørenskog, Norvegia, 1478
- Completato
- Akershus universitetssykehus
-
Oslo, Norvegia, 0379
- Reclutamento
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Amsterdam, Olanda, 1081 HV
- Reclutamento
- Amsterdam UMC locatie Vumc
-
Groningen, Olanda, 9713 GZ
- Reclutamento
- Universitair Medisch Centrum Groningen
-
Leiden, Olanda, 2333 ZG
- Reclutamento
- Leids Universitair Medisch Centrum
-
Maastricht, Olanda, 6229 HX
- Reclutamento
- Maastricht University Medical Center
-
Nijmegen, Olanda, 6525 GA
- Reclutamento
- Radboud University Medical Center
-
-
-
-
-
Cambridge, Regno Unito, CB2 0QQ
- Reclutamento
- Addenbrooke's Hospital
-
Coventry, Regno Unito, CV2 2DX
- Reclutamento
- University Hospital Coventry
-
London, Regno Unito, NW3 2QG
- Reclutamento
- Royal Free Hospital
-
London, Regno Unito, EC1A 7BE
- Reclutamento
- Barts Hospital
-
Nottingham, Regno Unito, NG5 1PB
- Reclutamento
- Nottingham City Hospital Campus
-
-
-
-
-
Barcelona, Spagna, 08036
- Reclutamento
- Hospital Clinic de Barcelona
-
Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitari Vall D'Hebron
-
Barcelona, Spagna, 08041
- Reclutamento
- Hospital de La Santa Creu I Sant Pau
-
Madrid, Spagna, 28041
- Reclutamento
- Hospital Universitario 12 de Octubre
-
Madrid, Spagna, 28034
- Reclutamento
- Hospital Universitario Ramon Y Cajal
-
Madrid, Spagna, 28009
- Reclutamento
- Hospital General Universitario Gregorio Marañon
-
Málaga, Spagna, 29010
- Reclutamento
- HOSPITAL REGIONAL UNIVERSITARIO de MALAGA AVDA.
-
Seville, Spagna, 41009
- Reclutamento
- Hospital Universitario Virgen Macarena
-
Valencia, Spagna, 46010
- Reclutamento
- Hospital Clinico Universitario de Valencia
-
-
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Reclutamento
- City of Hope
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06510
- Reclutamento
- Yale Cancer Center
-
-
Florida
-
Kissimmee, Florida, Stati Uniti, 34747
- Reclutamento
- AdventHealth Medical Group Oncology Research at Celebration
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Reclutamento
- University of Illinois Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21205
- Reclutamento
- Johns Hopkins University
-
Rockville, Maryland, Stati Uniti, 20850
- Reclutamento
- Maryland Oncology Hematology, PA
-
-
Minnesota
-
Saint Louis Park, Minnesota, Stati Uniti, 55426
- Reclutamento
- Health Partners Frauenshuh Cancer Center
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Reclutamento
- Health Partners Cancer Center at Regions Hospital
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University, School of Medicine
-
-
New York
-
Buffalo, New York, Stati Uniti, 14203
- Reclutamento
- Roswell Park Cancer Institute IDS
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Hospital
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- SCRI Oncology Partners
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- The University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Completato
- Fred Hutchinson Cancer Center
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Reclutamento
- Kaohsiung Chang Gung Memorial Hospital
-
Taichung, Taiwan, 407219
- Reclutamento
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- Reclutamento
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 11217
- Reclutamento
- Taipei Veterans General Hospital
-
Contatto:
- See Central Contact
-
Taipei, Taiwan, 100225
- Reclutamento
- National Taiwan University Hospital
-
Taipei, Taiwan, 11209
- Reclutamento
- Koo Foundation Sun Yat-Sen Cancer Center
-
Taipei, Taiwan, 104217
- Reclutamento
- MacKay Memorial Hospital
-
Taoyuan, Taiwan, 333
- Reclutamento
- Chang Gung Memorial Hospital
-
-
-
-
-
Kecskemét, Ungheria, 6000
- Reclutamento
- Bacs-Kiskun Varmegyei Oktatokorhaz
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
Participants must meet all of the following criteria to be eligible for enrollment into the study:
-
Sign and date the informed consent form prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all subjects to meet the baseline tumor tissue requirement.
-
Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
-
Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows:
Cutaneous (acral and non-acral) melanoma
-
Histologically or cytologically confirmed cutaneous (acral or non-acral) melanoma
-
Disease progression while on or after having received treatment with ≥1 prior line of anti-programmed cell death protein (PD-1) or anti-programmed death-ligand 1 (PD-L1) based therapy (previous use of other immune checkpoint inhibitors [ICIs] [ie, anti-CTLA4, anti- LAG-3] is acceptable). Prior anti-PD-(L)1 therapy in the adjuvant setting is allowed if there is recurrence within 12 weeks of the last dose. If the participant had BRAFm melanoma, they must have had disease progression on BRAF/MEK inhibitor therapy as well.
Squamous cell carcinomas of the head and neck
-
Squamous cell carcinoma of the head and neck (with a primary location of oral cavity,oropharynx, larynx, hypopharynx) that is human papillomavirus (HPV) positive or negative (as determined by local standard). Excludes tumor location in the nasopharynx, nasal cavity, paranasal sinuses, and unknown primary locations.
-
Disease progression after having received treatment with ≥1 and <3 prior lines of systemic therapy in the unresectable recurrent or metastatic setting.
Must have had disease progression on anti-PD-(L)1 (either as monotherapy or in combination with chemotherapy or other therapies). Must also have had disease progression on a platinum-based chemotherapy (PBC) regimen either in the recurrent or metastatic setting or in the locally advanced setting with curative intent.
Gastric or GEJ adenocarcinoma
-
Tumor tissue must be confirmed as negative for HER2 expression (immunohistochemistry [IHC] 0/1+ or IHC 2+/in situ hybridization negative) as classified by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.
-
Disease progression after having received treatment with ≥2 prior lines of therapy that include PBC with or without anti-PD-1 therapy.
Ovarian Carcinoma
-
Pathologically documented high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
-
Documented disease progression ≥4 weeks after the last dose of PBC and <6 months of last dose of PBC in the advanced or metastatic setting. Prior use of folate reductase alpha targeting antibody-drug conjugate (ADC) (ie, mirvetuximab soravtansine) is allowed.
Cervical Cancer
-
Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the uterine cervix.
-
Disease progression after having received ≥1 line of systemic therapy in the recurrent or metastatic setting. This may include prior anti-PD-(L)1 treatment and/or tissue factor directed ADC (tisotumab vedotin [TV]) per regional standard of care.
Endometrial Cancer
-
Pathologically or cytologically documented endometrial cancer (carcinoma of any histological sub-type or endometrial carcinosarcoma), irrespective of microsatellite instability (MSI) or mismatch repair (MMR) status.
-
Documented disease progression after having received ≥1 prior line of therapy (maximum of 3) PBC containing systemic treatment and an anti-PD(L)-1 therapy-containing regimen (combined or sequential) in the advanced/metastatic setting.
Bladder Cancer
-
Pathologically or cytologically documented locally advanced/unresectable or metastatic urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra. Histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology.
-
Relapsed or progressed after treatment with ≥1 prior line of therapy (maximum of 3) that contains anti-PD-(L)1 therapy in the perioperative or metastatic setting. At least 1 line of therapy must also contain one of the following treatment modalities: chemotherapy or enfortumab vedotin. Prior fibroblast growth factor receptor (FGFR)-inhibitor treatment for those who are eligible are allowed.
- Required treatments can be given in combination or sequentially
- Prior cisplatin-based therapy or PD-(L)1 inhibitor therapy given for the treatment of muscle invasive urothelial carcinoma is counted as 1 line of therapy
- The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy
- Participants in the second-line setting who have previously received enfortumab vedotin and pembrolizumab in combination can be enrolled.
Esophageal Carcinoma
-
Pathologically or cytologically documented esophageal squamous cell carcinoma.
-
Must have documented disease progression after having received 2 prior lines of therapy including previous PBC with or without an anti-PD-1 therapy-containing regimen (combined or sequential) in the advanced/metastatic setting.
Pancreatic Carcinoma
-
Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma.
-
Relapsed or disease progression after having received 1 prior line of systemic therapy in the locally advanced/metastatic setting.
Prostate Cancer
-
Pathologically or cytologically documented unresectable locally advanced or metastatic castration-resistant prostate cancer (CRPC).
-
Adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology.
-
Surgically or medically castrated, with testosterone levels of <50 ng/dL.
-
Documented objective progression as determined by radiographic progression for subjects with measurable disease after androgen deprivation.
-
Relapsed or disease progression after having received treatment with ≥1 of the following novel hormonal agents: abiraterone, enzalutamide, apalutamide, or darolutamide.
-
Relapsed or disease progression after having received ≥1 cytotoxic chemotherapy regimen that included a taxane.
Gastric Cancer 2L
-
Must have had gastric or GEJ adenocarcinoma confirmed as negative for HER2 expression (IHC 0/1+ or IHC 2+/in situ hybridization negative) as classified by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.
-
Disease progression after having received treatment with only 1 prior line of systemic anti-cancer therapy that includes 5-FU-based chemotherapy with or without an anti-PD-1 therapy. For subjects whose tumors are claudin (CLDN) 18.2 positive, treatment with 5-FU based chemotherapy with CLDN18.2 directed therapy in the first-line setting is allowed.
Non-small Cell Lung Cancer aa. Histologically or cytologically documented metastatic or locally advanced nonsquamous NSCLC not amenable to curative surgery or radiation bb. Documentation of absence of actionable driver mutation (ie, ALK rearrangement, BRAF V600E mutation, EGFR-activating mutations [exon 19 deletion or L858R mutation], EGFR exon 20 insertion mutation, HER2 mutation, KRAS G12C mutation, MET exon 14 skipping mutation, NTRK 1/2/3 gene fusion, RET rearrangement, or ROS1 rearrangement). New testing for these genomic alterations is not required for Screening.
cc. Relapsed or disease progression after receiving only anti-PD-(L)1 and PBC (ie, platinum doublet) administered in combination or sequentially for metastatic disease.
Breast Cancer dd. Pathologically documented breast cancer that is assessed as HER2 negative (IHC2+/ISH-, IHC1+, or IHC0 per ASCO/CAP guidelines), and HR positive (either ER and/or PgR positive [ER or PgR ≥1%] per ASCO/CAP guidelines). The HER2 and HR results must be from a tumor sample obtained in the metastatic setting.
ee. Participant must have received one line of chemotherapy for mBC, but not more than one line and must have a clinically or radiologically documented evidence of tumor progression on or after CDK 4/6 inhibitor combined with endocrine therapy; previous treatments with phosphoinositide 3-kinase (PI3K) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, protein kinase B (PKB) inhibitors also known as AKT-inhibitors and poly ADP ribose polymerase (PARP)-inhibitors are allowed.
-
-
Has ≥1 measurable lesion on CT or MRI as per RECIST v1.1 by investigator assessment. Prostate cancer participants with bone only disease may be eligible.
-
Provides a pretreatment tumor tissue sample that meets 1 of the following collection requirements:
-
Tumor biopsy from ≥1 lesion not previously irradiated and performed since progression with the most recent systemic cancer therapy regimen and prior to signature of the tissue ICF (ARCHIVAL PRETREATMENT sample).
OR
-
Newly obtained pretreatment tumor biopsy from ≥1 lesion not previously irradiated and amenable to sampling, after signature of tissue ICF (FRESH PRETREATMENT sample)
-
-
Has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at screening.
Exclusion Criteria
Participants who meet any of the following criteria will be disqualified from entering the study:
-
Has HER2-positive gastric cancer as classified by ASCO-CAP guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.
-
Has nasopharyngeal cancer.
-
Has mucosal or uveal melanoma.
-
Has a history of (non-infectious) interstitial lung disease (ILD), that required corticosteroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
-
Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
-
Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone daily or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1.
Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.
-
Had prior treatment with an anti-HER3 antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan).
-
Has history of other active malignancy within 3 years prior to Cycle 1 Day 1, except the following:
- Adequately treated nonmelanoma skin cancer
- Adequately treated intraepithelial carcinoma of the cervix
- Any other curatively treated in situ disease
-
Has any evidence of severe or uncontrolled diseases (eg, active bleeding diatheses, active serious infection) psychiatric illness/social situations, geographical factors, substance abuse, or other factors that, in the investigator's opinion, make it high risk for the subject to participate in the study or that would jeopardize compliance with the protocol
-
Has previously received topoisomerase-1 inhibitors (e.g., irinotecan) treatment in the advanced or metastatic disease setting.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: HER3-DXd Monotherapy
Participants with locally advanced unresectable or metastatic cancer (melanoma, head and neck, gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer) will receive an intravenous infusion of HER3-DXd monotherapy 5.6 mg/kg every 3 weeks (Q3W). |
Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proporzione di partecipanti che hanno ottenuto una riduzione ≥50% del PSA (solo coorte con cancro alla prostata)
Lasso di tempo: Basale, ogni ciclo prima dell'infusione (ogni ciclo dura 21 giorni) e fine del trattamento, fino a circa 27 mesi
|
Basale, ogni ciclo prima dell'infusione (ogni ciclo dura 21 giorni) e fine del trattamento, fino a circa 27 mesi
|
|
|
Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Lasso di tempo: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
|
Confirmed objective response rate (ORR) is defined as the sum of the complete response (CR) rate and partial response (PR) rate based on investigator by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. |
Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sopravvivenza libera da progressione valutata dallo sperimentatore dopo la monoterapia con HER3-DXd (tutte le coorti tranne la coorte con cancro alla prostata)
Lasso di tempo: Dalla data di inizio della somministrazione del farmaco in studio alla data precedente della prima documentazione obiettiva della progressione radiografica della malattia valutata dallo sperimentatore secondo RECIST v1.1 o della morte per qualsiasi causa, a seconda di quale evento si verifichi per primo, fino a circa 27 mesi
|
Dalla data di inizio della somministrazione del farmaco in studio alla data precedente della prima documentazione obiettiva della progressione radiografica della malattia valutata dallo sperimentatore secondo RECIST v1.1 o della morte per qualsiasi causa, a seconda di quale evento si verifichi per primo, fino a circa 27 mesi
|
|
|
Sopravvivenza globale dopo monoterapia con HER3-DXd (tutte le coorti)
Lasso di tempo: Dalla data di inizio della somministrazione del farmaco in studio alla data di morte per qualsiasi causa, a seconda di quale evento si verifichi per primo, fino a circa 27 mesi
|
Dalla data di inizio della somministrazione del farmaco in studio alla data di morte per qualsiasi causa, a seconda di quale evento si verifichi per primo, fino a circa 27 mesi
|
|
|
Sopravvivenza libera da progressione radiografica (rPFS) valutata dai criteri del Prostate Cancer Working Group 3 (PCWG3) da parte dello sperimentatore o decesso dovuto a qualsiasi causa in seguito alla monoterapia con HER3-DXd (solo nella coorte del cancro alla prostata)
Lasso di tempo: Dalla data di inizio della somministrazione del farmaco in studio alla data precedente della prima documentazione obiettiva della progressione radiografica della malattia valutata secondo i criteri PCWG3 dallo sperimentatore o della morte per qualsiasi causa, a seconda di quale evento si verifichi per primo, fino a circa 27 mesi
|
Dalla data di inizio della somministrazione del farmaco in studio alla data precedente della prima documentazione obiettiva della progressione radiografica della malattia valutata secondo i criteri PCWG3 dallo sperimentatore o della morte per qualsiasi causa, a seconda di quale evento si verifichi per primo, fino a circa 27 mesi
|
|
|
Proporzione di partecipanti che hanno ottenuto una riduzione ≥ 30% del PSA (solo coorte con cancro alla prostata)
Lasso di tempo: Basale, ogni ciclo prima dell'infusione (ogni ciclo dura 21 giorni) e fine del trattamento, fino a circa 27 mesi
|
Basale, ogni ciclo prima dell'infusione (ogni ciclo dura 21 giorni) e fine del trattamento, fino a circa 27 mesi
|
|
|
Tempo alla prima terapia antitumorale successiva (TFST) (solo nella coorte del cancro alla prostata)
Lasso di tempo: Dalla data di inizio della somministrazione del farmaco in studio all'inizio della prima terapia antitumorale successiva o al decesso, a seconda di quale evento si verifichi per primo, fino a circa 27 mesi
|
Dalla data di inizio della somministrazione del farmaco in studio all'inizio della prima terapia antitumorale successiva o al decesso, a seconda di quale evento si verifichi per primo, fino a circa 27 mesi
|
|
|
Tempo al primo evento sintomatico correlato all'apparato scheletrico (SSRE) (solo nella coorte del cancro alla prostata)
Lasso di tempo: Dalla data di inizio della somministrazione del farmaco in studio alla prima occorrenza di uno qualsiasi dei seguenti: Utilizzo di EBRT, Nuova frattura ossea patologica sintomatica, Compressione del midollo spinale, Intervento chirurgico ortopedico correlato al tumore, fino a circa 27 mesi
|
Dalla data di inizio della somministrazione del farmaco in studio alla prima occorrenza di uno qualsiasi dei seguenti: Utilizzo di EBRT, Nuova frattura ossea patologica sintomatica, Compressione del midollo spinale, Intervento chirurgico ortopedico correlato al tumore, fino a circa 27 mesi
|
|
|
Overall Number of Participants With Treatment-emergent Adverse Events Following HER3-DXd Monotherapy (All Cohorts)
Lasso di tempo: Baseline up to 27 months
|
Adverse events (AEs) will be coded using MedDRA and AEs and will be graded by using NCI-CTCAE v5.0. |
Baseline up to 27 months
|
|
Duration of Response As Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Lasso di tempo: From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 27 months
|
Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first documentation of progressive disease (PD) or death. The DoR will be calculated for responding participants (PR or CR) only. |
From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 27 months
|
|
Clinical Benefit Rate As Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Lasso di tempo: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
|
Clinical benefit rate (CBR) is the proportion of participants with a best overall response of confirmed CR, confirmed PR, or SD lasting ≥183 days. |
Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
|
|
Disease Control Rate As Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Lasso di tempo: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
|
Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD (or non-CR/non-PD) by investigator assessment per RECIST v1.1. |
Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
|
|
Time to Response As Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Lasso di tempo: From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 27 months
|
Time to response (TTR) will be calculated for confirmed responders only. |
From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 27 months
|
|
Pharmacokinetic Parameter Maximum Serum Concentration for HER3-DXd (All Cohorts)
Lasso di tempo: Cycles 1-4, 6, 8: Day 1, predose and postdose; Cycles 1 and 3: Day 1, 2 hours and 4 hours postdose; Cycles 1 and 3: Day 8, Day 15 (each cycle is 21 days)
|
Maximum serum concentration (Cmax) will be assessed using non-compartmental methods. |
Cycles 1-4, 6, 8: Day 1, predose and postdose; Cycles 1 and 3: Day 1, 2 hours and 4 hours postdose; Cycles 1 and 3: Day 8, Day 15 (each cycle is 21 days)
|
|
Pharmacokinetic Parameter Time to Maximum Serum Concentration for HER3-DXd (All Cohorts)
Lasso di tempo: Cycles 1-4, 6, 8: Day 1, predose and postdose; Cycles 1 and 3: Day 1, 2 hours and 4 hours postdose; Cycles 1 and 3: Day 8, Day 15 (each cycle is 21 days)
|
Time to maximum serum concentration (Tmax) will be assessed using non-compartmental methods. |
Cycles 1-4, 6, 8: Day 1, predose and postdose; Cycles 1 and 3: Day 1, 2 hours and 4 hours postdose; Cycles 1 and 3: Day 8, Day 15 (each cycle is 21 days)
|
|
Pharmacokinetic Parameter Trough Serum Concentration (Ctrough) for HER3-DXd (All Cohorts)
Lasso di tempo: Cycles 1-4, 6, 8: Day 1, predose and postdose; Cycles 1 and 3: Day 1, 2 hours and 4 hours postdose; Cycles 1 and 3: Day 8, Day 15 (each cycle is 21 days)
|
Trough serum concentration (Ctrough) will be assessed using non-compartmental methods. |
Cycles 1-4, 6, 8: Day 1, predose and postdose; Cycles 1 and 3: Day 1, 2 hours and 4 hours postdose; Cycles 1 and 3: Day 8, Day 15 (each cycle is 21 days)
|
|
Pharmacokinetic Parameter Area Under the Concentration Curve for HER3-DXd (All Cohorts)
Lasso di tempo: Cycles 1-4, 6, 8: Day 1, predose and postdose; Cycles 1 and 3: Day 1, 2 hours and 4 hours postdose; Cycles 1 and 3: Day 8, Day 15 (each cycle is 21 days)
|
Area under the concentration-time curve up to the last quantifiable time (AUClast) and Area under the concentration-time curve during dosing interval (AUCtau) will be assessed using non-compartmental methods. |
Cycles 1-4, 6, 8: Day 1, predose and postdose; Cycles 1 and 3: Day 1, 2 hours and 4 hours postdose; Cycles 1 and 3: Day 8, Day 15 (each cycle is 21 days)
|
|
Correlation Between HER3 Protein Expression and Efficacy
Lasso di tempo: From the start date of study drug up to approximately 27 months
|
HER3 protein expression in tumor tissue as determined by IHC and correlation with ORR, DoR, and PFS. |
From the start date of study drug up to approximately 27 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Direttore dello studio: Global Clinical Leader, Daiichi Sankyo
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Neoplasie genitali, maschio
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie genitali, maschio
- Malattie della prostata
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Malattie uterine
- Malattie genitali, femmina
- Malattie polmonari
- Neoplasie delle ghiandole endocrine
- Malattie pancreatiche
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Malattie esofagee
- Malattie ovariche
- Malattie annessiali
- Neoplasie genitali, femmina
- Disturbi gonadici
- Malattie della pelle
- Malattie del seno
- Neoplasie urologiche
- Malattie della cervice uterina
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Neoplasie uterine
- Tumori neuroendocrini
- Nevi e melanomi
- Neoplasie cutanee
- Malattie della vescica urinaria
- Malattie della pelle e del tessuto connettivo
- Neoplasie prostatiche
- Neoplasie allo stomaco
- Neoplasie polmonari
- Neoplasie esofagee
- Neoplasie ovariche
- Neoplasie mammarie
- Neoplasie pancreatiche
- Carcinoma, polmone non a piccole cellule
- Neoplasie cervicali uterine
- Neoplasie della testa e del collo
- Melanoma
- Neoplasie della vescica urinaria
- Neoplasie endometriali
- Patritumab Deruxtecan
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- U31402-277
- 2023-507641-29-00 (Altro identificatore: EU CTIS)
- jRCT2031230575 (Altro identificatore: jRCT)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Periodo di condivisione IPD
Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Criteri di accesso alla condivisione IPD
Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .